Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Cash & Equivalents (2019 - 2026)

ADC Therapeutics has reported Cash & Equivalents over the past 8 years, most recently at $231.0 million for Q1 2026.

  • Quarterly results put Cash & Equivalents at $231.0 million for Q1 2026, up 18.65% from a year ago — trailing twelve months through Mar 2026 was $231.0 million (up 18.65% YoY), and the annual figure for FY2025 was $261.3 million, up 4.17%.
  • Cash & Equivalents reached $231.0 million in Q1 2026 per ADCT's latest filing, down from $261.3 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $310.5 million in Q1 2023 and bottomed at $326441.0 in Q3 2023.
  • Median Cash & Equivalents over the past 5 years was $234.7 million (2025), compared with a mean of $184.4 million.
  • The largest annual shift saw Cash & Equivalents plummeted 99.91% in 2022 before it skyrocketed 86257.23% in 2024.
  • Over 5 years, Cash & Equivalents stood at $298.2 million in 2022, then dropped by 6.57% to $278.6 million in 2023, then decreased by 9.95% to $250.9 million in 2024, then grew by 4.17% to $261.3 million in 2025, then fell by 11.61% to $231.0 million in 2026.
  • Business Quant data shows Cash & Equivalents for ADCT at $231.0 million in Q1 2026, $261.3 million in Q4 2025, and $234.7 million in Q3 2025.